News

On July 9, 2026, AstraZeneca and Ionis reported that the phase 3 CARDIO-TTRansform trial of eplontersen (Wainua) did not meet its primary efficacy endpoint in…

Department of Vascular Surgery, Beijing Haidian Hospital, Beijing, People’s Republic of China; 2Department of Hematology, Beijing Chao-Yang Hospital, Capital…

Attruby (acoramidis), an approved therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), may help preserve kidney function in adults with the rare heart…

IntroductionAmyloidosis of the heart is a rare but serious condition that can significantly impact your cardiovascular health. It involves an abnormal buildup of…

AbstractAccurate amyloid typing in cardiac amyloidosis is clinically important for determining treatment strategies. A 73-year-old man underwent a renal biopsy due…

A new analysis suggests acoramidis may improve kidney health over time in people with transthyretin amyloid cardiomyopathy (ATTR-CM). BridgeBio Pharma, the company…

CARLSBAD, Calif.--(BUSINESS WIRE)--Jul. 9, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform…

HighlightsSubtle age-related ATTR-CM can complicate preexisting other HF etiologies.Combined cardiomyopathies can present with atypical clinical/imaging…

SummaryOnce rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly treatable. Basic scientific…

The efficacy of diflunisal for the treatment of hereditary transthyretin amyloidosis (ATTR) was confirmed by data from the Swedish ATTR registry, according to…